Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cholinesterase inhibitors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Cholinesterase inhibitors. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-003219-23 Sponsor Protocol Number: 2844 Start Date*: 2019-06-28
    Sponsor Name:University of Bristol
    Full Title: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
    Medical condition: This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001477-94 Sponsor Protocol Number: 3098B1-203 Start Date*: 2006-05-08
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000569-61 Sponsor Protocol Number: CHUBX2016/27 Start Date*: 2021-12-20
    Sponsor Name:CHU de Bordeaux
    Full Title: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial
    Medical condition: Alzheimer disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002938-73 Sponsor Protocol Number: ARGX-113-1602 Start Date*: 2016-10-31
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
    Medical condition: Myasthenia Gravis who have Generalized Muscle Weakness
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003997-18 Sponsor Protocol Number: GTI1408 Start Date*: 2015-07-07
    Sponsor Name:Grifols Therapeutics Inc.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (IGIV -C) in Symptomatic Su...
    Medical condition: Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021218-50 Sponsor Protocol Number: AB09004 Start Date*: 2011-05-25
    Sponsor Name:AB Science
    Full Title: A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease
    Medical condition: mild to moderate Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012271 Dementia Alzheimer's type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prohibited by CA) ES (Completed) SK (Prohibited by CA) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005765-11 Sponsor Protocol Number: 523001.01.078 Start Date*: 2006-04-12
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Randomised, double-blind, placebo-controlled, parallel group trial to confirm the efficacy, safety and tolerability of Ginkgo biloba Special Extract EGb 761® in patients suffering from Mild Mental ...
    Medical condition: Mild Mental Impairment
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004946-27 Sponsor Protocol Number: E2020-A001-219 Start Date*: 2017-05-18
    Sponsor Name:Eisai Inc.
    Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D...
    Medical condition: Down Syndrome, Cognitive Dysfunction
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002179-21 Sponsor Protocol Number: AB21004 Start Date*: 2022-10-07
    Sponsor Name:AB Science
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzhei...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 100000004852 10001896 Alzheimer's disease LLT
    24.1 100000004852 10086384 Early onset Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) GR (Completed) PL (Prematurely Ended) PT (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005995-14 Sponsor Protocol Number: 3133K1-3001-WW(B2521002) Start Date*: 2009-05-29
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005994-79 Sponsor Protocol Number: 3133K1-3000-WW Start Date*: 2008-05-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...
    Medical condition: Enfermedad de Alzheimer Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003383-47 Sponsor Protocol Number: TAK-079-1005 Start Date*: 2020-08-12
    Sponsor Name:MILLENNIUM PHARMACEUTICALS, INC.
    Full Title: A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005442-20 Sponsor Protocol Number: E2020-G000-334 Start Date*: 2008-09-04
    Sponsor Name:Eisai Limited
    Full Title: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment
    Medical condition: Attention impairment after cancer treatment
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005435-28 Sponsor Protocol Number: E2020-G000-333 Start Date*: 2008-09-03
    Sponsor Name:Eisai Limited
    Full Title: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment
    Medical condition: Attention impairment after cancer treatment
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) NL (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002764-27 Sponsor Protocol Number: NILVAD2012 Start Date*: 2013-02-04
    Sponsor Name:St James's Hospital
    Full Title: A European multicenre double-blind placebo controlled phase III trial of nilvadipine in mild to moderate Alzheimer's disease.
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) GR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004384-31 Sponsor Protocol Number: SAG/0211PFC-11S1 Start Date*: 2015-06-10
    Sponsor Name:Sucampo AG
    Full Title: A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥6 to <18 years with Functional Constipation
    Medical condition: functional constipation in paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Ongoing) NL (Completed) FR (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022991-29 Sponsor Protocol Number: SMR/0211OBD-1033 Start Date*: 2011-02-01
    Sponsor Name:Sucampo Pharma Americas, Inc.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction
    Medical condition: Opioid-induced Bowel Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10061247 Intestinal functional disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-000097-35 Sponsor Protocol Number: CCFZ533X2204 Start Date*: 2015-09-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moder...
    Medical condition: Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bi...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004335-36 Sponsor Protocol Number: ANAVEX2-73-PDD-001 Start Date*: 2018-07-04
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.
    Medical condition: Cognition in Parkinson’s Disease with dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:45:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA